LoginSignup
ME

23andMe Stock

StockStock
ISIN: US90138Q3065
Ticker: ME
US90138Q3065
ME

Price

Frequently asked questions

What is 23andMe's market capitalization?

The market capitalization of 23andMe is $102.41M. Market capitalization is a measure of the total market value of a publicly traded company. It is calculated by multiplying the current stock price by the total number of outstanding shares.

What is the Earnings Per Share (EPS) for 23andMe?

23andMe's Earnings Per Share (EPS) over the trailing twelve months (TTM) is -$26.13. EPS indicates the company's profitability on a per-share basis.

What are the analyst ratings and target price for 23andMe's stock?

Currently, 2 analysts cover 23andMe's stock, with a consensus target price of $26.30. Analyst ratings provide insights into the stock's expected performance.

What is 23andMe's revenue over the trailing twelve months?

Over the trailing twelve months, 23andMe reported a revenue of $199.19M.

What is the EBITDA for 23andMe?

23andMe's Earnings before interest, taxes, depreciation, and amortization (EBITDA) over the trailing twelve months is -$272.74M. EBITDA measures the company's overall financial performance.

What is the free cash flow of 23andMe?

23andMe has a free cash flow of -$146.49M. Free cash flow indicates the cash generated after accounting for cash outflows to support operations and capital assets.

What is the 5-year beta of 23andMe's stock?

The 5-year beta for 23andMe is 1.23. A beta value indicates the stock's volatility relative to the market; a beta greater than 1 means higher volatility.

How many employees does 23andMe have, and what sector and industry does it belong to?

23andMe employs approximately 560 people. It operates in the Health Care sector, specifically within the Healthcare Facilities industry.

What is the free float of 23andMe's shares?

The free float of 23andMe is 22.21M. Free float refers to the number of shares available for public trading, excluding restricted shares.

Financials

Market Cap

 $102.41M

5Y beta

 1.23

EPS (TTM)

 -$26.13

Free Float

 22.21M

Revenue (TTM)

 $199.19M

EBITDA (TTM)

 -$272.74M

Free Cashflow (TTM)

 -$146.49M

Pricing

52W span
$4.21$20.40

Analyst Ratings

The price target is $26.30 and the stock is covered by 2 analysts.

Buy

1

Hold

1

Sell

0

Information

23andMe Holding Co. is a genetics-led consumer healthcare and biopharmaceutical company. The Company operates through two segments: Consumer & Research Services and Therapeutics. The Consumer & Research Services business segment comprises its Personal Genome Service (PGS), telehealth business, and research service. PGS services provide customers with a broad suite of genetic reports, including information on customers’ genetic ancestral origins, personal genetic health risks, and chances of passing on certain rare carrier conditions to their children, as well as reports on how genetics can impact responses to medications. The Therapeutics business segment focuses on the use of genetic insights from databases of genetic and phenotypic information to develop novel therapies to improve patients’ lives. The Therapeutics segment consists of out-licensing of intellectual property associated with identified drug targets and expenses related to therapeutic product candidates.

560

Healthcare Facilities

Health Care

Identifier

ISIN

US90138Q3065

Primary Ticker

ME
Join the conversation
Sign upLogin